510(k) Report

510(k) · Cleared

Cleared

CareSuperb™ COVID-19 Antigen Home Test

K241915510(k) TraditionalCleared Jan 29, 2025212-day reviewClass II21 CFR 866.3984

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Access Bio, Inc. · QYT Over-The-Counter Covid-19 Antigen Test

Cleared on Jan 29, 2025 as substantially equivalent to K230828 (ACON Laboratories, Inc., 2023) after a 212-day review. Its family tree reaches back 1 generation to 2023.

Decided
Jan 29, 2025
Review
212 days
Class
Class II
Product code
QYT
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K230828 (2023). No later device cites it as a predicate yet.

  1. Root · 1 generation backK230828 Flowflex COVID-19 Antigen Home TestACON Laboratories, Inc. · 2023
  2. This deviceK241915 CareSuperb™ COVID-19 Antigen Home TestAccess Bio, Inc. · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K230828Flowflex COVID-19 Antigen Home TestACON Laboratories, Inc.2023—
0 (this device)K241915CareSuperb™ COVID-19 Antigen Home TestAccess Bio, Inc.2025—
FIG. 1 — Lineage of K241915, 2023–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QYT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QYT device

  1. #1 K241313 OHC COVID-19 Antigen Self Testscore 12.4 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K230828Flowflex COVID-19 Antigen Home Test
Summary page 5
…iology 3. Legally Marketed Predicate Device 3.1. Trade Name: Flowflex COVID-19 Antigen Home Test 3.2. Manufacturer: ACON Laboratories, Inc. 3.3. 510(k) Number: K230828 3.4. Product Code: QYT 3.5. Review Panel: Microbiology 4. Device Description The CareSuperb™ COVID-19 Antigen Home Test…
ACON Laboratories, Inc.2023—

Also cleared against K230828: 6 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • 6 other devices also cite its predicate K230828.

How does its category compare?

All QYT devices

QYT Over-The-Counter Covid-19 Antigen Test: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · QYT

5in 2025

2023: 12024: 52025: 52026 (partial year): 3
2007high 5 (2024) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QYT

138in 2025

2024: 179 days median2025: 138 days median2026 (partial year): 90 days median
2007high 179 (2024) · low 138 (2025)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QYT

No recall names QYT since 2007.

Adverse event reports per year · QYT

82in 2025

2024: 232025: 82
2007high 82 (2025) · low 0 (2007)2025

MAUDE reports naming product code QYT, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20231—00
20245179023
20255138082
20263900—

What is it indicated for?

The CareSuperb COVID-19 Antigen Home Test is a visually read lateral flow immunoassay device intended for the rapid, qualitative detection of SARS-CoV-2 virus nucleocapsid protein antigen directly in anterior nasal swab specimens from individuals with signs and symptoms of COVID-19. This test is for non-prescription home use by individuals aged 14 years or older testing themselves, or adults testing individuals aged 2 years or older. All negative results…

Read the full statement (239 words)

The CareSuperb COVID-19 Antigen Home Test is a visually read lateral flow immunoassay device intended for the rapid, qualitative detection of SARS-CoV-2 virus nucleocapsid protein antigen directly in anterior nasal swab specimens from individuals with signs and symptoms of COVID-19.

This test is for non-prescription home use by individuals aged 14 years or older testing themselves, or adults testing individuals aged 2 years or older.

All negative results are presumptive. Symptomatic individuals with an initial negative test result must be re-tested once between 48 and 72 hours after the first test using either an antigen test or a molecular test for SARS-CoV-2. Negative results do not rule out SARS-CoV-2 infections or other pathogens and should not be used as the sole basis for treatment.

Positive results do not rule out co-infection with other respiratory pathogens.

This test is not a substitute for visits to a healthcare provider or appropriate follow-up and should not be used to determine any treatments without provider supervision. Individuals who test negative and experience continued or worsening COVID-19 symptoms, such as fever, cough and/or shortness of breath, should seek follow up care from their healthcare provider.

Performance characteristics for SARS-CoV-2 were established from October 2023 to April 2024 when SARS-CoV-2 Omicron variant was dominant. Test accuracy may change as new SARS-CoV-2 viruses emerge. Additional testing with a lab-based molecular test (e.g., PCR) should be considered in situations where a new virus or variant is suspected.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K241915: CareSuperb™ COVID-19 Antigen Home Test.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K241915

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026